#1 Clinical Trials Search in Europe

Ovolecithin

This article discusses a clinical trial investigating the use of a drug containing Ovolecithin, along with other substances, in treating children with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). The study aims to compare the effects of triheptanoin with medium-chain triglycerides (MCT) on major clinical events in pediatric patients with LC-FAOD.

Table of Contents

What is OVOLECITHIN?

OVOLECITHIN, also known as egg lecithin, is a component of a medical product being studied for the treatment of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)[1]. It is part of a fat emulsion that includes other substances such as glycerol, doconexent (also called docosahexaenoic acid), icosapent (also known as eicosapentaenoic acid), and DL-alpha-tocopherol (a form of vitamin E)[1].

Understanding Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) are a group of rare genetic metabolic conditions. In these disorders, the body has difficulty breaking down certain fats into energy, particularly during periods without food (fasting) or during illness[1]. This can lead to various health problems, including:

  • Hypoglycemia (low blood sugar)
  • Rhabdomyolysis (breakdown of muscle tissue)
  • Cardiomyopathy (heart muscle disease)

These conditions can be severe and potentially life-threatening, especially in children[1].

Clinical Trial Information

A clinical trial (study number 2023-509809-76-00) is being conducted to evaluate a new treatment approach for children with LC-FAOD[1]. This study is comparing two treatments:

  1. Triheptanoin: An investigational drug
  2. Medium-chain Triglycerides (MCT): A type of fat that’s easier for people with LC-FAOD to process

The product containing OVOLECITHIN is part of the MCT treatment in this study[1].

Treatment Approach

The treatment being studied is an oral liquid that contains medium-chain triglycerides (MCT)[1]. This fat emulsion includes OVOLECITHIN along with other components. The maximum daily dose is 35% of the patient’s total caloric intake[1].

The idea behind this treatment is to provide an alternative energy source that can be more easily processed by individuals with LC-FAOD, potentially reducing the frequency and severity of metabolic crises[1].

Eligibility Criteria

The study is focused on children with LC-FAOD. Some key eligibility criteria include[1]:

  • Confirmed diagnosis of LC-FAOD
  • Age from 0 (including newborns) to less than 18 years
  • History of significant clinical manifestations of LC-FAOD, such as metabolic crises or susceptibility to hypoglycemia

There are additional criteria for inclusion and exclusion in the study, which a healthcare provider can explain in detail[1].

Study Objectives and Endpoints

The main goal of the study is to evaluate how effective the treatment is in reducing the frequency of major clinical events (MCEs) related to LC-FAOD[1]. Other objectives include:

  • Assessing the effect on the duration of MCEs
  • Evaluating the impact on hypoglycemic events
  • Measuring changes in overall health status and functioning
  • Assessing the effect on cardiomyopathy events

The study will also look at quality of life measures and the safety of the treatment[1].

Potential Benefits and Considerations

While the specific benefits of OVOLECITHIN in this treatment are not detailed, the overall approach aims to provide a more easily metabolized energy source for children with LC-FAOD. This could potentially lead to[1]:

  • Fewer metabolic crises
  • Reduced frequency and severity of symptoms
  • Improved quality of life

However, as with any medical treatment, there may be risks and side effects. The study is designed to carefully monitor participants for any adverse events[1].

It’s important to note that this is an investigational treatment, and its effectiveness and safety are still being evaluated. Patients and caregivers should discuss the potential benefits and risks with their healthcare providers[1].

Aspect Details
Study Type Randomized, double-blind, multicenter study
Condition Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Age Group 0 to <18 years
Investigational Drug Triheptanoin (contains Ovolecithin)
Control Drug Medium-chain Triglycerides (MCT)
Primary Objective Evaluate effect on frequency of Major Clinical Events (MCEs)
Secondary Objectives Assess duration of MCEs, frequency of hypoglycemic events, change in overall health status, effect on cardiomyopathy MCEs, and more
Administration Oral use
Maximum Daily Dose 35%
Maximum Treatment Period 24 months

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the effect of triheptanoin compared to medium-chain triglycerides (MCT) on the frequency of major clinical events in children with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD).
  • What age group does this study focus on? The study focuses on males and females from birth (including newborns) to less than 18 years of age who have been diagnosed with LC-FAOD.
  • What are some of the inclusion criteria for participants? Some inclusion criteria include a confirmed diagnosis of LC-FAOD, having significant clinical manifestations of LC-FAOD (such as severe episodes of metabolic decompensation or evidence of functional cardiomyopathy), and having a caregiver willing to assist with study requirements.
  • How is the study designed? The study is designed as a randomized, double-blind, active-controlled, Phase 3 study. This means that participants are randomly assigned to either the investigational drug or the control drug, and neither the participants nor the researchers know which treatment each participant is receiving.
  • What is Ovolecithin and how is it used in this study? Ovolecithin, also known as egg lecithin, is one of the active substances in the investigational drug. It is part of a fat emulsion that is being studied for its potential effects on LC-FAOD. The drug is administered orally and compared to medium-chain triglycerides (MCT) to assess its impact on major clinical events in patients with LC-FAOD.

Ongoing Clinical Trials on Ovolecithin

  • Study on the Effects of Triheptanoin and Medium-chain Triglycerides in Children with Long-chain Fatty Acid Oxidation Disorders

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Poland Spain

Glossary

  • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD): A group of rare genetic metabolic disorders that affect the body's ability to break down long-chain fatty acids for energy. This can lead to various health problems, especially during periods of fasting or illness.
  • Triheptanoin: An investigational drug being studied for its potential to treat LC-FAOD by providing an alternative energy source for the body.
  • Medium-chain Triglycerides (MCT): A type of fat that is more easily digested and absorbed by the body compared to long-chain triglycerides. In this study, MCT is used as the control treatment to compare with triheptanoin.
  • Major Clinical Events (MCEs): Significant health issues related to LC-FAOD, such as hypoglycemia (low blood sugar), rhabdomyolysis (breakdown of muscle tissue), or cardiomyopathy (heart muscle disease).
  • Ovolecithin: Also known as egg lecithin, it is one of the active substances in the investigational drug being studied. It is a type of fat that may help in the treatment of LC-FAOD.
  • Randomized, Double-blind Study: A type of clinical trial where participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know which treatment each participant is receiving. This helps to reduce bias in the study results.
  • Hypoglycemia: A condition characterized by abnormally low blood sugar levels, which can be a serious complication in patients with LC-FAOD.
  • Cardiomyopathy: A group of diseases that affect the heart muscle, making it harder for the heart to pump blood to the rest of the body. This can be a complication of LC-FAOD.
  • Rhabdomyolysis: A serious condition resulting from the breakdown of skeletal muscle fibers with leakage of muscle contents into the bloodstream. This can occur in patients with LC-FAOD, especially during periods of metabolic stress.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-triheptanoin-and-medium-chain-triglycerides-in-children-with-long-chain-fatty-acid-oxidation-disorders/